Connected With Latham

Latham & Watkins

In each episode of Connected With Latham, we discuss ideas, developments, and trends shaping the global economy.

  1. 2d ago

    Drug Pricing and Market Access: Takeaways from the Medicaid Drug Rebate Program Summit 2026

    Stakeholders from across the healthcare industry recently convened in Chicago for the Medicaid Drug Rebate Program Summit 2026. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott discusses key takeaways from the conference with Amanda Forys, Managing Partner at Magnolia Market Access, and Sabrina Aery, Founder at Aery Policy & Access Partners. Topics include Most Favored Nation pricing developments, the evolving 340B landscape, Average Sales Price reporting, and the implementation of the Inflation Reduction Act.   Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

  2. Oct 8

    The Growth Rocketship: Deep Research, Bold Bets, and AI — Inside Maverick Capital's $15 Billion Portfolios

    Built on a foundation of deep fundamental research and data-driven insights, Maverick Capital manages over US$15 billion across three distinct pillars: Public Equities, Ventures, and Silicon. Since launching in 2015, Maverick has backed breakout companies in healthcare, biotech, and technology from seed stage through IPO, including SiMa.ai and TensorWave. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with Trevor Wiessmann, General Counsel and Chief Compliance Officer at Maverick Capital, to explore Trevor's journey from published novelist to overseeing legal and compliance at a US$15 billion-plus firm, the investment philosophy behind Maverick's portfolios, and the macro trends in AI and infrastructure shaping today's markets.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

    The Growth Rocketship: Deep Research, Bold Bets, and AI — Inside Maverick Capital's $15 Billion Portfolios
  3. Sep 30

    Shining a Light on the Sunshine Act and Transparency Requirements: A Primer for Life Sciences Companies

    The US Physician Payments Sunshine Act requires life sciences companies to publicly report payments, transfers of value, and ownership interests. In the first episode of our Shining a Light on the Sunshine Act and Transparency Requirements series, Washington, D.C. counsel Nicole Liffrig Molife and associate Megan Lich walk listeners through the fundamentals of Sunshine Act compliance, including who is required to report, what types of payments and ownership interests must be reported, and key deadlines and compliance strategies.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

  4. Sep 21

    Drug Pricing and Market Access: The RAPID Pathway

    The Centers for Medicare & Medicaid Services (CMS) proposed the Regulatory Alignment for Predictable and Immediate Device (RAPID) pathway to coordinate FDA device approval and Medicare coverage decisions under one coordinated process from the start — aiming to shrink a historically five-year gap to as few as 60-90 days. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott and Nate Beaton, along with associate Danny Machado, break down how RAPID works, how it differs from prior coverage initiatives, and what device manufacturers should consider as the pathway takes shape.   Also check out our bi-weekly Drug Pricing Digest on the website or subscribe to receive future editions in your inbox.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

  5. Sep 17

    The Growth Rocketship: Brave Capital, Defense Tech, Decisive Technologies!

    San Francisco-based venture capital firm Brave Capital partners with companies from pre-seed through growth equity stages, backing transformative technology startups in sectors ranging from AI to aerospace and energy. The firm backs modern defense disruptors — known as "neoprimes" — that bridge the traditional military-industrial gap, with investments in companies such as Shield AI. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with Ernestine Fu Mak, Founder and Managing Partner of Brave Capital, to discuss the firm's approach to investing in decisive technologies, macro trends shaping AI and infrastructure, capital allocation strategies across early- and late-stage investments, and what drives one of the most dynamic investors in Silicon Valley history.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

    The Growth Rocketship: Brave Capital, Defense Tech, Decisive Technologies!
  6. Sep 3

    The Growth Rocketship: Hercules Backs Tech, Life Sciences

    Hercules Capital provides senior secured loans to high-growth, venture capital-backed companies across technology and life sciences. Since its inception in 2003, Hercules has committed more than US$28 billion to more than 700 companies and works with more than 1,000 leading venture capital and private equity firms. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with Scott Bluestein, Chief Executive Officer and Chief Investment Officer of Hercules Capital, to discuss Hercules' investment approach, the role of venture debt in the current market, and how AI could shape the future of technology and life sciences markets.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

    The Growth Rocketship: Hercules Backs Tech, Life Sciences
  7. Aug 14

    Europe Litigation: Mass Actions at a Global Scale

    Europe has entered the collective redress era. The full implementation of the EU Representative Actions Directive, coupled with a surge in litigation funding, has transformed the ability of claimant groups to coordinate across jurisdictions. Companies now face the prospect of parallel consumer, data privacy, and competition actions that are global in scope — which means the challenge for defendants is not just winning individual cases, but managing consistency of arguments, data strategies, and settlement approaches across multiple fronts. In this episode of Connected With Latham, London partners Oliver Middleton and Nell Perks and Hamburg partner Christoph Baus discuss how the EU Representative Actions Directive affects mass actions, the UK's response to the Directive, and what clients can do to navigate potential challenges.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

  8. Jun 30

    The Growth Rocketship: Inside Boutique Venture With NewView Capital

    California-based venture capital and growth firm with more than US$3 billion under management, NewView Capital invests in high-potential technology companies on a primary, secondary, or hybrid basis. Founded in 2018, NewView has emerged as an early leader in the secondary market, taking a boutique, high-conviction approach to backing category-defining companies. Latham has advised NewView on a range of primary, secondary, and hybrid investments across the US and around the world. In this episode of Connected With Latham, Haim Zaltzman, Global Vice Chair of Latham's Emerging Companies & Growth Practice, sits down with NewView Capital Partner Ankit Sud to discuss the firm's thematic investment philosophy, its leadership in the secondary market, and how NewView helps portfolio companies reinvent themselves in the AI era.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

    The Growth Rocketship: Inside Boutique Venture With NewView Capital

Ratings & Reviews

4.6
out of 5
16 Ratings

About

In each episode of Connected With Latham, we discuss ideas, developments, and trends shaping the global economy.

You Might Also Like